Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1).
暂无分享，去创建一个
M. Climent | N. Gibson | A. Font | R. Lorence | F. Solca | J. Virizuela | R. Morales-Barrera | A. González-del-Alba | A. Rodríguez-Vida | J. Serra | Francisco X. Real | Stéphane Oudard | Begoña Mellado | Javier Puente | Daniel Castellano | Alvaro Pinto | P. L. Fernandez | Cristina Teixido | P. Jares | I. Aldecoa | Shoubhik Mondal | S. Oudard | A. Pinto